Navigation Links
New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted at American College of Rheumatology Meeting
Date:11/7/2011

atients with active Crohn's disease who have not responded adequately to conventional treatment in September 2007.

Please visit www.cimzia.com for full prescribing information for CIMZIA®.

IMPORTANT SAFETY INFORMATION

Risk of Serious Infections and Malignancy

Patients treated with CIMZIA are at an increased risk for developing serious infections that may lead to hospitalization or death.  Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.  CIMZIA should be discontinued if a patient develops a serious infection or sepsis.  Reported infections include:

  • Active tuberculosis, including reactivation of latent tuberculosis.  Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.  Patients should be tested for latent tuberculosis before CIMZIA use and during therapy.  Treatment for latent infection should be initiated prior to CIMZIA use.  
  • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.  Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized disease.  Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection.  Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
  • Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with CIMZIA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.  Patients s
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development
4. Reportlinker Adds Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
5. Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
6. Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
7. Improvements in Recurrence-Free Survival in Early Stages of Colorectal Cancer Will Limit Growth of Drug Treatment Opportunities for Advanced Disease
8. Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinsons Disease
9. Ekahau RTLS Enables Improvements in Staff Safety in Austrian Psychiatric Hospital
10. Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months
11. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... MUMBAI, India , June 19, ... Book Bureau has recently added DrugPatentWatch ... Databases. ( http://www.bharatbook.com/drugpatentwatch-tour.pdf ) ... DrugPatentWatch provides comprehensive information on pharmaceutical, ... value-added information supports the critical business ...
(Date:6/19/2013)... --  Nektar Therapeutics (Nasdaq: NKTR ) today ... study for NKTR-181, a first-in-class, opioid analgesic molecule ... slow rate of entry is designed to reduce the euphoria ... current opioid analgesics. 1 In the study data being ... in "drug liking" and "feeling high" scores and had highly ...
(Date:6/19/2013)... June 19, 2013 BD Biosciences, a segment of ... a leading global medical technology company, today announced the launch ... latest in its line of high-performance research flow cytometers. ... multicolor analysis with the most compact footprint in its class ... a height of 30" (76.2 cm). Recognizing that space is ...
Breaking Medicine Technology:Drug Patent Watch 2Drug Patent Watch 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
(Date:6/19/2013)... of three important studies have been published in the ... the Congress of Neurological Surgeons . The ... , a part of Wolters Kluwer Health . ... artificial neural networks (ANNs) may improve the ability to ... study in the June Neurosurgery supports increased ...
(Date:6/19/2013)... 2013) In early April, senior leaders from medical, ... Connecticut, to discuss one question: how can first responders ... , The preliminary results of this discussion are now ... The Hartford Consensus ," a concept paper published in ... of Trauma and Acute Care Surgery , official ...
(Date:6/19/2013)... Could drugs that block the body,s system for repairing ... to health? As unlikely as it may seem, those ... and breast cancers driven by a mutation in BRCA, ... revealed she carries the mutation. The compounds, termed PARP ... the current edition of Chemical & Engineering News ...
(Date:6/19/2013)... 19, 2013 PREFERRED Therapy Providers, Inc. ... Arizona to offer a new Medicare Advantage Plan ... Paz, Yavapai and Mohave, Arizona counties. The agreement takes ... effective January 1, 2013 and Maricopa and Pima counties ... Inc., the parent company of WellCare of Arizona has ...
(Date:6/19/2013)... Kansas City will host its first Ciclovia event on Sept. ... section of Main Street in the midtown area will be restricted ... The Main Street Corridor Development and BikeWalkKC ... join the ranks of dozens of cities across the US and ... vibrancy and active lifestyles. , “Ciclovia is the perfect event for ...
Breaking Medicine News(10 mins):Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3
... shows , , THURSDAY, Sept. 13 (HealthDay News) -- The HIV ... of sexual partners, U.S. researchers report. , More than half ... 2005 were among gay men, a team at the University ... in five gay men living in cities may be HIV-positive. ...
... Clinic,s,Multidisciplinary Simulation Center is now one of 11 ... be accredited by,the American College of Surgeons (ACS). ... advance medical education that will improve patient,safety by ... pace with,rapidly changing technologies. Mayo,s 10,000-square-foot, state-of-the-art ...
... Drug Control Policy to Include Meth Project ... of New Anti-Methamphetamine Initiative, PALO ALTO, Calif., Sept. 13 ... have been,selected by the White House Office of National Drug ... campaign. The Anti-Meth Campaign was unveiled today by ONDCP ...
... Lowering Kevin Everett,s body temperature helped protect his spinal ... -- As Buffalo Bills football player Kevin Everett was ... with a life-threatening spinal cord injury, he was already ... paralysis. , Everett,s spinal cord was damaged in his ...
... been named,mid-Atlantic region sales executive for AllOne Health ... their employees to take,greater control over their health ... employers alike. (Photo: http://www.newscom.com/cgi-bin/prnh/20070912/NEW120 ) ... Nicholas Hanchak, M.D.,Decker joins the team being headed ...
... Ensure Company Data Safe, Provide Alternate Operations ... Facility in Case ... largest,provider of business services to orthodontic and dental practices,worldwide, has ... Texas, as part of the company,s efforts to strengthen its,infrastructure ...
Cached Medicine News:Health News:Number of Partners Doesn't Explain Gay HIV Rate 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 3Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 2Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 3Health News:Meth Project Advertisements Selected for National Prevention Campaign 2Health News:Meth Project Advertisements Selected for National Prevention Campaign 3Health News:Novel Cooling Therapy May Have Aided Injured Football Player 2Health News:Novel Cooling Therapy May Have Aided Injured Football Player 3Health News:Novel Cooling Therapy May Have Aided Injured Football Player 4Health News:Frances Decker Named Mid-Atlantic Region Sales Executive for AllOne Health Management Solutions 2Health News:OrthoSynetics(TM) Opens New Data Center, Colocation Facility 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: